Condition: Prostate Cancer · Metabolic Syndrome · Obesity · Sponsor: Western University
The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm. 2. To confirm tolerability and assess for side effects of oral acetate supplementation. 2. Secondary outcomes: 1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.
This description comes directly from the study's public registry record.
Kaydee Connors · 519-685-8500 · kaydee.connors@lhsc.on.ca
Stephen Mardell · 519-685-8500 · stephen.mardell@lhsc.on.ca
Always discuss trial participation with your own doctor first.
| London Health Sciences Centre - Victoria Hospital | London, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05802121